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Abstract
Background: We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in
hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting in amplified FGFR4 signaling
in HCC remain under-studied. Here, we studied the mechanistic role of its co-receptor klotho-beta (KLB) in driving
elevated FGFR4 activity in HCC progression.
Results: Quantitative real-time PCR analysis identified frequent elevation of KLB gene expression in HCC tumors
relative to matched non-tumor tissue, with a more than two-fold increase correlating with development of
multiple tumors in patients. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4
downstream signaling. While transient repression of KLB-FGFR4 signaling decreased protein expression of alpha-
fetoprotein (AFP), a HCC diagnostic marker, prolonged inhibition enriched for resistant HCC cells exhibiting
increased liver stemness.
Conclusions: Elevated KLB expression in HCC tissues provides further credence to the oncogenic role of increased
FGFR4 signaling in HCC progression and represents a novel biomarker to identify additional patients amenable to
anti-FGFR4 therapy. The restricted tissue expression profile of KLB, together with the anti-proliferative effect
observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. The
enrichment of a liver stem cell-like population in response to extended KLB-FGFR4 repression necessitates further
investigation to target the development of drug resistance.
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Introduction
With approximately 680,000 deaths in 2008, hepatocel-
lular carcinoma (HCC) ranks third worldwide in cancer-
related mortalities [1]. The majority of HCC patients
present at advanced stages where curative surgical treat-
ments are not applicable and face median survival of
less than a year [2]. Moreover, traditional systemic che-
motherapies have produced no significant survival bene-
fit in advanced HCC patients [3]. Consequently, novel
therapies for unresectable HCC are urgently needed to
address this grim prognosis.
Recently, there has been increasing interest in devel-
oping molecular-targeted therapies that can discriminate
between cancer cells and their non-neoplastic counter-
parts by targeting proteins overexpressed in tumors.
The approval of sorafenib, a multi-targeted tyrosine
kinase inhibitor, for the treatment of advanced-stage
HCC patients in 2007 highlights the potential of such
therapies in treating this complex neoplasia [4]. Further-
more, the success of sorafenib has intensified efforts in
identifying receptor tyrosine kinase (RTK) genes fre-
quently and selectively upregulated in HCC [5,6].
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blast growth factor receptor-4 (FGFR4). Within the
FGFR family, FGFR4 is the dominant isoform expressed
in mature hepatocytes and is expressed at higher levels
in the liver compared to other organs [7,8]. Amplified
FGFR4 signaling has been reported in head-and-neck
squamous cell carcinoma [9], and has also been linked
to accelerated tumor progression in breast and colon
cancers [10]. Transgenic mouse models demonstrated
that ectopic expression of FGF19, a FGFR4-specific
ligand, promotes hepatocyte proliferation and sponta-
neous HCC development [11]. In agreement with these
studies, our group previously found elevated FGFR4
expression in HCC tumors and demonstrated that dys-
regulated FGFR4 signaling promotes proliferation [12].
T h e s ef i n d i n g ss t r o n g l yi m p l i c a t ea b n o r m a lF G F R 4
activity in HCC progression.
A key regulator of the FGFR4 pathway is its co-recep-
tor klotho-beta (KLB), a 130 kDa trans-membrane pro-
tein that exhibits a more restricted expression profile in
adipose, liver and pancreas tissues [8]. KLB and FGFR4
are both expressed at high levels in mature hepatocytes
[8], where KLB stabilizes FGF19-FGFR4 binding to regu-
late production of cholesterol 7a-hydroxylase (CYP7A1)
and hepatocyte proliferation [8,11,13]. Also, KLB
-/- and
FGFR4
-/- knockout mice exhibit similar features such as
increased CYP7A1 expression and small gallbladder size,
demonstrating an intimate role of KLB in mediating
FGFR4 activity in hepatocytes [14-16]. Given the con-
tributory role of FGFR4 in HCC progression, we specu-
late that dysregulated KLB expression in HCC may
function as an additional mechanism resulting in ampli-
fied FGFR4 signaling. While previous studies on KLB in
hepatocytes focused mainly on its metabolic functions
[8,13,17], this is the first study investigating its role in
HCC progression.
We detected elevated KLB expression in HCC tumors
that correlated with multi-foci formation. Repression of
KLB expression suppressed FGFR4 downstream signal-
ing and significantly inhibited hepatoma cell prolifera-
tion. Intriguingly, we observed biomarkers suggestive of
an elevated liver stemness behavior in Huh7 hepatoma
cells after prolonged repression of KLB-FGFR4 signaling.
The discovery of amplified KLB expression in HCC
expands upon our previous work demonstrating dysre-
gulated FGFR4 signaling in HCC progression. The
enrichment of cells expressing stemness markers in
response to FGFR4 inhibition highlights the need to
characterize this stem-like population and elucidate the
underlying resistance mechanisms. This information will
be instrumental in identifying the repertoire of HCC-
specific pathways to be targeted concurrently with
FGFR4 signaling to achieve effective treatment.
Materials and methods
Reagents
FGFR inhibitor PD173074 (Calbiochem, San Diego, CA)
was re-suspended in DMSO and stored at -20°C.
Cell culture
HepG2, Sk-Hep1, Hep3B, PLC/PRF/5, Hs817.T, THLE2
were obtained from ATCC (Manassas, VA) while Huh7
was obtained from the Max Planck Institute (Martins-
ried, Germany). HepG2, Hep3B, PLC/PRF/5 cells were
maintained in MEM supplemented with 10% FBS,
sodium pyruvate and non-essential amino acids, THLE2
in BEGM (Lonza, Basel, Switzerland) and the rest in
DMEM with 10% FBS and sodium pyruvate. Huh7 cells
were cultured for eight weeks in PD173074 (0.1 μM-
1.0 μM) to generate resistant HCC cells. Cells were
maintained at 37°C in 5% CO2. Unless stated otherwise,
reagents were obtained from Invitrogen (Life Technolo-
gies, Grand Island, NY).
HCC patient sample preparation
T o t a lR N Aw a si s o l a t e df r o m5 6p a i r e dt u m o r sa n d
adjacent non-tumor liver tissues from HCC patients at
the National University Hospital (Singapore) as pre-
viously described in accordance with ethics guidelines
[12]. The National Healthcare Group Institutional
Review Board approved this study. cDNAs were synthe-
sized using SuperScript III reverse transcriptase (Invitro-
gen, Carlsbad, CA) according to manufacturer’s
instructions.
Gene expression analysis
Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed in triplicates on the ABI7500 Fast
Real-Time PCR system (Applied Biosystems, Foster
City, CA) with Power SYBR Green PCR Master Mix
(ABI). The following gene-specific primer pairs were
used:
KLB (NM_175737.3): (F) 5’-GCAGTCAGACCCAA-
GAAAATACAGA-3’,
(R) 5’-CCCAGGAATATCAGTGGTTTCTTC-3’;
AFP (NM_001134.1), (F) 5’-AGCTTGGTGGTGGAT-
GAAAC-3’,
(R) 5’-TCTTGCTTCATCGTTTGCAG-3’;
CD133 (NG_011696.1), (F) 5’-CCTGGGGC-
TGCTGTTTATTA-3’,
(R) 5’-TACCTGGTGATTTGCCACAA-3’,
CD44 (NG_008937.1), (F) 5’-CGGACACCATGGA-
CAAGTTT-3’,
(R) 5’-GAAAGCCTTGCAGAGGTCAG-3’;
FGFR4 (NG_012067.1), (F) 5’-CAAAGA-
CAACGCCTCTGACA-3’,
(R) 5’- CACCAAGCAGGTTGATGATG-3’;
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CATGGGTGTGAA-3’,
(R) 5’-TGTGGTCATGAGTCCTTCCA-3’
Gene expression was analyzed with the 2
-ΔΔCt formula
after normalizing to GAPDH.
Liver tumor tissue lysates
Protein lysates of matched normal and tumor liver tis-
sues were obtained from Protein Biotechnologies
(Ramona, CA).
Immunoblotting
Cells were lysed in buffer (50 mM HEPES, 150 mM NaCl,
1 mM EDTA, 10% glycerol, 1% TritonX-100, 10 mM
sodium pyrophosphate) containing protease and phospha-
tase inhibitors (10 mM sodium fluoride, 2 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 0.1
μg/mL aprotinin). Protein concentrations were determined
by the BCA method (Pierce-Thermo Fisher Scientific,
Rockford, IL) and equal amounts were resolved with 7.5%
SDS-PAGE before electro-transferring to PVDF or nitro-
cellulose membranes. After blocking, blots were incubated
in antibodies diluted in PBS with 0.05% (v/v) Tween 20
and 5% (w/v) non-fat milk or bovine serum albumin
(BSA). Primary antibodies used were anti-proliferating cell
nuclear antigen PCNA (P10) from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA), phospho-FRS2a, anti-phospho-p44/
42 ERK1/2, anti-phospho-Akt antibodies from Cell Signal-
ing Technology (Beverly, MA), anti-CD133 from Miltenyi
Biotec GmbH (Bergisch Gladbach, Germany) and anti-b-
tubulin 1 from Sigma (St Louis, MO). Blots were visua-
lized after incubation with secondary anti-mouse and anti-
rabbit HRP-conjugated antibodies (Pierce) by enhanced
chemiluminescence (Pierce).
Gene silencing by siRNA and shRNA
24 h after seeding (2 × 10
5 cells/well) in a six-well plate,
cells were transfected with 100 nM non-targeting control
siRNA (D-0018010-10), KLB-targeting (D-017848-01) or
FGFR4-targeting (J-003134-15) siRNA from Dharmacon
(Chicago, IL) according to manufacturer’s instructions.
Gene knockdown was confirmed by qRT-PCR 48 h post-
transfection, and immunoblotting 72 h after transfection.
To establish stable FGFR4 knockdown clones, Huh7 cells
were transfected with pRS vector control (TR20003, Ori-
gene Technologies, Rockville, MD) and FGFR4-specific
HuSH 29mer shRNA constructs (TR320356, Origene) and
selected with 2 μg/mL puromycin (Sigma) for at least 14
days as previously described [12].
Cell proliferation assay
48 h post-transfection with KLB-targeting siRNA, eight
replicates (7500 cells/well) were seeded in a 96-well
plate. After 24 h, CellTiter-Glo luminescent assay
(Promega, Madison, WI) was performed to measure
ATP content as a gauge of viable cells.
Statistical analysis
All categorical data was tested with Fisher’s exact prob-
ability test. Differences in transcript levels were analyzed
using Student’s t test of ΔCt values or one-way ANOVA
and Tukey’s multiple comparison tests. Comparisons of
KLB mRNA, protein levels between paired tumor and
normal tissues were carried out by non-parametric Wil-
coxon matched paired test. All statistical analyses were
performed using GraphPad Prism software (GraphPad
Software Inc, San Diego, CA). Patient clinicopathological
parameters, provided in Additional file 1: Table S1,
including tumor multiplicity, age, gender, etiology, dis-
ease outcome, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alpha-fetoprotein (AFP) levels,
tumor histology and diameter, presence of cirrhosis and
vascular invasion were evaluated. Statistical significance
is defined as P < 0.05.
Results
KLB expression is frequently upregulated in HCC
Using qRT-PCR, we studied KLB mRNA levels in 56
human HCC tumors and their adjacent paired normal
liver tissues to identify expression level changes that
accompany cancer progression (Figure 1A, Table 1).
Upregulated KLB expression (> 2-fold) in tumor tissue
was observed in 25% of HCC samples and paired t-test
analysis indicates an overall statistically significant
increase in KLB expression in HCC tumors (Wilcoxon
matched pairs test, P < 0.01, Figure 1B). We found no
significant correlation of KLB gene expression with
FGFR4 previously determined from the same patient
population [12] (Spearman rank correlation: r = 0.032; P
= 0.812). We also performed in silico analysis of pub-
lished microarray data from Oncomine http://www.
oncomine.org that revealed KLB overexpression in
tumors relative to adjacent normal tissues in HCC
patients and also livers from normal patients (Additional
file 2: Figure S1). As shown in Figure 1C, analysis of
KLB protein expression in an independent set of paired
HCC liver lysates revealed KLB up-regulation in HCC
tumors relative to adjacent normal tissues, which con-
curs with our qRT-PCR and in silico results. Protein
levels are statistically different between HCC tumors
and paired normal tissues (Wilcoxon matched pairs test,
P < 0.05, Figure 1D right panel).
Increased KLB expression associates with the
development of multiple HCC tumors
To determine the clinical relevance of elevated KLB
expression in HCC patients, we correlated the clinico-
pathological features between patients with upregulated
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the respective HCC tissues. Fisher’s exact test results
indicate that KLB overexpression significantly correlated
with multi-foci manifestation in patients (P <0 . 0 5 ,
Table 1). There was no significant correlation with
other clinicopathological parameters.
HCC cell lines show KLB gene overexpression
We next evaluated KLB mRNA expression in six HCC
cell lines and a normal liver cell line THLE2. In
agreement with our clinical findings, KLB was overex-
pressed in four HCC cell lines (Huh7, HepG2, Hep3B,
PLC/PRF/5) (Figure 1E). SK-Hep1 was shown to be of
endothelial origin lacking hepatic-specific features,
which may explain the lack of concordance with other
HCC cell lines [18]. We selected Huh7, which exhibited
the highest KLB gene expression, to study the contribu-
tion of KLB to FGFR4 signaling and HCC progression.
Moreover, we previously found a homozygous FGFR4
G388R polymorphism in Huh7 that is linked to
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Figure 1 KLB expression is upregulated in HCC tumors and cell lines. (A) Analysis of KLB gene expression using qRT-PCR in tumor tissue
relative to its matched normal tissue after normalizing to GPADH mRNA. Fold change of < 0.5 indicates down-regulation of KLB expression
while > 2-fold change indicates KLB up-regulation in tumors. (B) Wilcoxon signed rank test was used to analyze the difference of KLB gene
expression in paired normal (Δ) and tumor liver tissues (○). (C) KLB protein expression was determined in Huh7 cells and an independent set of
paired HCC lysates. The ratio of KLB between tumor and normal tissue was calculated as (tumor KLB/normal KLB) after normalizing the protein
band density to b-actin. (D) The Wilcoxon signed rank test was used to analyze the difference in KLB/b-actin expression between the two
groups. (E) KLB mRNA expression in HCC cell lines are expressed as fold changes relative to THLE2 with error bars representing standard
deviation (SD) converted to fold changes. (***, P < 0.001 using Student’s t-test).
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vides a good culture model to study the effects of KLB
perturbation in a more aggressive setting.
Silencing KLB expression decreases HCC cell growth via
cell cycle arrest
Having noted elevated KLB expression in HCC patients
and cell lines, we evaluated the effect of RNAi targeting
K L Bo nc e l lg r o w t hi nH u h 7 .W ec o n f i r m e de f f e c t i v e
silencing at the transcript (Figure 2A) and protein levels
(Figure 3) in cells transfected with KLB-targeting siRNA.
Since KLB can also stimulate activation of FGFR1c, 2c,
3c and 4 [13], we selected CYP7A1, a physiological tar-
get specifically repressed by FGFR4 in hepatocytes [19],
as a marker of FGFR4 activity. We validated KLB-silen-
cing on FGFR4 signaling by showing that CYP7A1 was
upregulated by more than 3-fold (Additional file 3: Fig-
ure S2). More importantly, KLB-silenced cells displayed
more than 50% reduction in proliferation compared to
cells transfected with control siRNA (Figure 2B). Next,
we analyzed the growth curve of Huh7 cells and
observed statistically significant growth suppression in
cells transfected with KLB-targeting siRNA at day 4 and
5 post-transfection (P < 0.05, Figure 2C). Decreased
Table 1 Correlation of KLB expression and tumor multiplicity in HCC patients
Down-regulated KLB expression (× <
0.5-fold)
mRNA change not significant (2.0 > ×
> 0.5)
Up-regulated KLB expression (×
> 2.0)
p-
value
N = 10 (17.86%) N = 32 (57.14%) N = 14 (25%)
Tumor
multiplicity:
Single tumor 8 22 4 0.02
Multiple tumors 21 0 1 0
Median age 53.5 59.5 55.3 0.23
Gender:
Female 1 7 3 0.81
Male 92 5 1 1
Etiology
HBV 7 23 11 1.00
HCV 02 1
Alcohol 01 0
Outcome
Alive 3 11 4 0.93
Death 41 0 3
Recurrence 16 3
Mean ALT (U/
ml)
47.8 65.3 48.5 0.58
Mean AST (U/
ml)
63.8 70.6 67 0.95
Mean AFP (U/
ml)
45550 19734 14240 0.43
Tumor
histology:
Poor 5 9 1 0.72
Well 15 0
Mean diameter 10.03 8.35 9.32 0.64
Cirrhosis:
Positive 7 19 11 0.43
Negative 31 3 3
Vascular
Invasion:
Yes 7 16 7 0.52
No 21 3 4
Using the classification in Figure 1 to stratify patients based on KLB expression in HCC tumors relative to their respective normal tissues, Fisher’s exact test was
performed with respect to clinicopathological features.
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tion is due to cell cycle arrest in these cells (Figure 2D).
Decreased KLB expression inhibits FGFR4 downstream
signaling
Activated FGFRs phosphorylate the docking protein FGF
receptor substrate-2a (FRS2a), which then activates the
Ras-Raf-ERK1/2 MAPK and PI-3 kinase pathways
responsible for cell proliferation and survival. Huh7 cells
express high levels of FGFR4 and exhibit significant
basal phosphorylation of FRS2a in the absence of
FGF19 stimulation, hence this cell model allows us to
study the effects of KLB suppression independent of the
influence of FGF19 [12]. At 72 h post siRNA transfec-
tion, we observed decreased KLB protein expression
with a corresponding reduction in phosphorylated
FRS2a, ERK1/2 and Akt proteins, indicative of
decreased FGFR4 signaling (Figure 3).
siRNA-mediated silencing of KLB decreases AFP protein
levels with an increase in transcript levels of AFP and
stemness associated genes CD133, CD44
Next, we monitored the protein levels of AFP, a clini-
cally relevant HCC biomarker, in Huh7 cells after
siRNA-mediated silencing of either KLB or FGFR4. In
KLB- or FGFR4-silenced cells, AFP protein expression
decreased (Figure 4A), mirroring previous work showing
suppressed AFP secretion with inhibition of FGFR4 sig-
naling [12]. The weaker suppression on AFP protein
expression in KLB-silenced cells compared to cells
transfected with FGFR4-targeting siRNA could be due
to a compensatory elevation of FGFR4 expression with
KLB suppression (Additional file 4: Figure S3). Intrigu-
ingly, we observed an increase of 170% and 20% in AFP
mRNA expression in KLB- and FGFR4-silenced cells
r e s p e c t i v e l y .T oi n v e s t i g a te the opposing effects that
inhibiting FGFR4 signaling has on AFP protein and
transcript levels, we considered the expression of AFP in
hepatic progenitor cells and its role in development of
stem-like features in HCC [20,21]. We postulated that
RNAi-mediated silencing of KLB or FGFR4 eliminated
the bulk hepatoma population exhibiting hyper-activated
FGFR4 signaling and AFP secretion, thereby resulting in
an overall decrease in AFP protein levels shown in Fig-
ure 4A. However, this strategy inadvertently enriched
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Figure 2 Silencing of KLB with siRNA suppresses cell viability
and proliferation. Huh7 cells were transfected with 100 nM
scrambled control or KLB-targeting siRNA. (A) After 48 h, qRT-PCR
was performed to confirm KLB knockdown after normalizing to
GAPDH. Error bars represent SD converted to fold changes. (B) At 48
h post transfection, Huh7 cells were re-seeded in a 96-well plate.
After additional 24 h incubation, cell viability was measured using
CellTiter-Glo and evaluated relative to cells transfected with
scrambled siRNA. (C) At the indicated time points after transfection,
Huh7 cells were harvested for counting. (D) Immunoblotting with
PCNA antibody was performed 72 h post siRNA transfection using
tubulin as loading control. For A-C, means of three independent
experiments are indicated with SD as error bars. (***, P < 0.001; *, P
< 0.05 using Student’s t-test).
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Figure 3 KLB mediates FGFR4 downstream signaling and
phosphorylation of pro-survival proteins. 72 h post-transfection
with siRNA, Huh7 cells were lysed, resolved with 7.5% SDS-PAGE
and immunoblotted using the indicated antibodies. Results are
indicative of two independent experiments.
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contributed to elevated AFP gene expression. To cir-
cumvent the dichotomy associated with AFP, we
decided to focus on CD133 and CD44, bona fide stem-
ness-associated genes in liver progenitor cells [22-24].
We observed a significant increase of 150% and 25% in
the expression of CD133 and CD44 genes respectively
in KLB-silenced Huh7 cells, strongly indicating an ele-
vated response in liver stemness gene expression (Figure
4C). CD133 protein expression also confirmed that KLB
suppression enriched for cells with higher CD133
expression (Figure 4D).
Stable repression of FGFR4 pathway increases CD133,
CD44 gene expression
Since KLB is a key regulator of the FGFR4 pathway in
hepatocytes, we examined CD133 and CD44 mRNA
expression in Huh7 cells with stables repression of
FGFR4 characterized previously [12]. qRT-PCR analysis
indicated a significant increase of 150% and 50% in
CD133 and CD44 expression in cells stably transfected
with FGFR4 shRNA compared to Huh7 cells expressing
control shRNA (Figure 4E).
Sustained exposure to sub-lethal concentrations of
PD173074, a FGFR inhibitor, selected for resistant cells
exhibiting a dose-dependent increase in CD133 and CD44
expression
Previously, we showed that PD173074, a non-selective
FGFR small molecule inhibitor, suppresses viability and
invasiveness more potently in HCC cells with high
endogenous FGFR4 expression [12]. Here, we deter-
mined if the increased stemness behavior with transient
and prolonged inhibition of FGFR4 signaling could be
observed with PD173074 treatment. We cultured Huh7
cells for eight weeks under sub-lethal concentrations of
PD173074 (0.1 μM-1 . 0μM )a n do b s e r v e dad o s e -
dependent increase in CD133 (Figure 5A) gene expres-
sion in PD-resistant Huh7 cells. A similar increase in
CD44 gene expression with higher doses was also noted,
with the exception at the lowest 0.1 μM dose (Figure
5B). CD133 protein expression was increased in the
resistant population consistent with the qRT-PCR
results (Figure 5C). FGFR4 and KLB protein levels in
PD-resistant cells were also significantly suppressed in a
dose-dependent manner (Figure 5D).
Discussion
HCC is a solid tumor lacking a dominant pathogenetic
event driving cancer development and progression. The
molecular complexity of this cancer warrants a multi-
disciplinary approach targeting multiple dysregulated
signaling pathways [5]. Aberrant activation of RTK sig-
naling has been observed in HCC and the clinical bene-
fits observed with sorafenib further support the efficacy
of targeting multiple RTK pathways in this disease [5,6].
As such, establishing a repertoire of pathways frequently
and selectively upregulated in tumor cells will facilitate
the development of more specific anti-cancer therapeu-
tics with minimal toxicity to non-malignant
counterparts.
Our lab has previously showed that frequent elevation
of FGFR4 expression occurs in HCC tumors and is
linked to increased proliferation and aggressiveness [12].
Yet, the understanding of FGFR4 signaling on hepato-
carcinogenesis remains divided with counter-evidence
suggesting that removal of FGFR4 delays diethylnitrosa-
mine-induced HCC formation [25-27]. This dichotomy
is likely marred by the complex interplay with other
tumor initiating factors in animal model systems, hence
we decided to base our study in a more relevant setting
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Figure 4 Silencing of KLB or FGFR4 increases expression of
liver stemness genes. (A) 48 h post siRNA silencing of KLB or
FGFR4 in Huh7 cells, AFP gene expression was determined by qRT-
PCR. Data indicates fold change in gene expression normalized to
scrambled siRNA. Error bars represent SD converted to fold changes.
(B) After 72 h, AFP protein expression was also determined using
polyclonal anti-AFP antibodies, normalized to b-actin as loading
control. (C) CD133 and CD44 expression after KLB-silencing was
subsequently determined as described for (A). (D) The effect of the
silencing on CD133 protein expression was performed using anti-
CD133 antibody. (E) CD133 and CD44 mRNA levels were measured
in Huh7 stable clones expressing control shRNA and FGFR4 shRNA
after normalizing to GAPDH.
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Page 7 of 10using human paired tumor/normal samples. To uncover
additional mechanisms amplifying FGFR4 activity in
HCC, we examined its co-receptor KLB which is
required for ligand binding and activation of FGFR4 sig-
naling in hepatocytes [8]. While others have investigated
the impact of KLB-FGFR4 signaling on bile acid meta-
bolic pathways in hepatocytes [8,13,15], details concern-
ing aberrations of KLB in HCC development are lacking.
In this study, we observed frequent elevation of KLB
expression in HCC tumors relative to paired normal
liver tissues and noted that KLB up-regulation corre-
lated with multiple tumor formation. We found a simi-
lar increase in KLB mRNA expression in HCC cell lines
as well as in published microarray data. Next, we con-
firmed increased KLB protein expression in an indepen-
dently obtained panel of HCC paired lysates. Taken
together, our findings suggest that increased KLB
expression is a frequent event in normal-to-tumor tran-
sition in hepatocytes. Although KLB has also been
known to activate FGFR1c, 2c, and 3c, there is a lack of
published evidence suggesting that activation of these
FGFRs has any pro-tumorigenic effect in hepatocytes
[13]. On the other hand, FGFR4 has been proposed as a
novel RTK target for HCC based on studies where
FGF19-mediated FGFR4 activation resulted in
hepatocyte proliferation and HCC formation [11,28]. In
this study, we built upon our previous work by focusing
on FGFR4 signaling and have uncovered a novel mole-
cular mechanism amplifying FGFR4 activity, further cor-
roborating a tumor-progressive role of dysregulated
FGFR4 activity in HCC.
To elucidate a role for KLB over-expression in HCC
tumors, we silenced KLB expression in Huh7 that has
the highest KLB level in our HCC cell line panel. More-
over, we previously reported that Huh7 cells are homo-
zygous for the FGFR4 G388R polymorphism linked to
increased aggressiveness [12]. Hence, we are able to
examine the effects of KLB perturbation in an aggressive
hepatoma model driven by elevated FGFR4 activity. We
observed a significant reduction in proliferation due to
cell cycle arrest and suppressed phosphorylation of
FRS2a, ERK1/2 and Akt with KLB-silencing. In cancer
cells, ERK1/2 activation increases expression of genes
promoting cell cycle progression while phosphorylated
Akt inhibits apoptosis [29,30]. Given the poor prognosis
in HCC patients exhibiting increased activation of
ERK1/2 and Akt, both pathways are attractive targets to
disrupt HCC progression [31]. Moreover, protein
expression of AFP, a HCC diagnostic marker, was
repressed when either FGFR4 or KLB was silenced,
which is consistent with our earlier finding where inhi-
bition of FGFR4 activity with PD173074 or RNAi silen-
cing of FGFR4 blocked AFP secretion [12]. Together,
these results underline a potent anti-tumor effect of
KLB inhibition in HCC. Importantly, the normal pheno-
type of KLB null mice, coupled with the restricted tissue
expression of KLB [14-16], suggests that systemic treat-
ment with KLB inhibitors should have minimal risk of
toxic effects in HCC patients.
Given the paradoxical increase in liver tumor marker
AFP transcription when either FGFR4 or KLB was
silenced, we considered AFP’s role in cellular de-differen-
tiation and stem-like behavior in HCC [21]. We propose
that the inhibition of FGFR4 signaling through KLB-silen-
cing in HCC cells eliminated the hyper-proliferative
FGFR4-overexpressing cell population, while enriching for
resistant cells with progenitor features. The disparity
between the transcript and protein expression could be a
temporal phenomenon due to the inhibitory effect of sup-
pressing FGFR4 signaling on AFP production with the
simultaneous emergence of a stem-like population. Hence,
we used established stem-cell markers CD133 and CD44
to avoid the confounding effects associated with AFP ana-
lysis. CD133 and CD44 are cell surface markers that have
been used to isolate progenitor cell sub-populations from
breast, colon and liver tumors that exhibit increased meta-
static potential, chemoresistance and tumorigenicity
[22-24,32]. In agreement with our finding, it has been
reported that CD133
+ cells are enriched in liver cancer
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Figure 5 CD133 and CD44 expression are upregulated in
PD173074-resistant cells. Resistant Huh7 cells were generated by
culturing in sub-lethal concentrations of PD173074 (0.1 μM - 1.0
μM). After eight weeks, (A) CD133 and (B) CD44 mRNA expression
were analyzed by qRT-PCR. Results are indicated with SD converted
to fold changes as error bars. The differences were statistically
significant (P < 0.001 by one-way ANOVA, P < 0.05 by Tukey’s
multiple comparison test). (C) CD133 protein expression was
determined by immunoblotting and normalized to b-actin. (D) Long
term effect of PD173074 treatment on FGFR4 and KLB protein
expression were determined by immunoblot assays. For (C) and (D),
the respective relative protein levels were calculated relative to
DMSO control after normalizing the protein band density to that of
the loading control.
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Page 8 of 10cell lines treated with traditional chemotherapy drugs dox-
orubicin and fluorouracil [32]. However, other work sug-
gests that CD133 may also be expressed in differentiated
tumor cells [33]. Therefore, we envisage a combination of
CD133 and CD44 as a more reliable characterization of
stem-like character, consistent with a notable report pro-
posing CD133
+ CD44
+ cells isolated from Huh7 as bona
fide cancer progenitor cells [24]. We found up-regulation
of CD133 and CD44 genes in KLB-silenced Huh7 cells
and in clones with stable repression of FGFR4 shRNA.
Similarly, we observed a dose-dependent increase in
CD133 and CD44 expression in resistant Huh7 clones cul-
tured under sub-lethal concentrations of FGFR inhibitor
PD173074. Overall, our work supports the notion that
while inhibition of FGFR4 signaling exerts acute and direct
anti-proliferative effects on HCC cells, the surviving sub-
population may be clonally selected for a resilient, stem
cell-like phenotype. Moving forward, analyzing the expres-
sion of other putative hepatic stem cell markers and in
vivo transplantation studies of these stem-like subpopula-
tions will benefit our understanding of the underlying
molecular characteristics imparting resistance.
In conclusion, elevated KLB expression in HCC
tumors contributes to malignant progression and repre-
sents an additional mechanism of aberrant FGFR4 sig-
naling in HCC. This result supports our previous
finding highlighting the oncogenic role of FGFR4 signal-
ing in HCC. The lack of overlap in KLB and FGFR4
overexpression in HCC tumors points to a larger popu-
lation of patients exhibiting elevated FGFR4 signaling,
affirming the need for FGFR4 pathway inhibitors. In this
study, the anti-proliferative outcome of repressing KLB
expression, coupled with its restricted tissue distribu-
tion, strongly points to KLB as a potent, more selective
and novel target for therapeutic intervention of aberrant
FGFR4 signaling in HCCs. In view of the increased
stemness gene expression observed with repression of
FGFR4 signaling, clinical development of FGFR4 inhibi-
tors will benefit from complementary therapeutics that
target the resistant liver stem cell-like population con-
currently to achieve superior outcome in HCC patients.
Additional material
Additional file 1: Table S1 Clinicopathological parameters of HCC
patients.
Additional file 2: Figure S1 KLB mRNA is overexpressed in HCC
(Oncomine expression array data). Expression of KLB mRNA in HCC
tissue relative to (A) adjacent non-tumor liver tissues [34] and (B) normal
liver tissues from normal patients [35].
Additional file 3: Figure S2 Upregulation of CYP7A1 mRNA in KLB-
silenced Huh7 cells. 48 h post siRNA transfection in Huh7 cells, CYP7A1
gene expression was measured by qRT-PCR and normalized to GAPDH.
Results are indicated with SD converted to fold changes as error bars.
Additional file 4: Figure S3 Decreased KLB and FGFR4 expression
with RNAi silencing. 48 h post siRNA silencing of (A) KLB and (B) FGFR4
in Huh7 cells, gene expression of KLB and FGFR4 were measured by qRT-
PCR and normalized to GAPDH. Results are indicated with SD converted
to fold changes as error bars.
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